<DOC>
	<DOC>NCT01576861</DOC>
	<brief_summary>After the encouraging results of 6 months of Growth Hormone Replacement Therapy in Patients With Chronic Heart Failure and Coexisting Growth Hormone Deficiency (NCT00591760) the investigators wanted to collect data about the long-term efficacy and safety of this kind of therapy.</brief_summary>
	<brief_title>Long-Term Efficacy and Safety of Growth Hormone Replacement Therapy in Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Chronic Heart Failure New York Heart Association functional class II to IV, secondary to ischemic or idiopathic cardiomyopathy Age range 1880 years Stable medication for at least one month including betablockers that had to be started at least 5 months before entering the study Left Ventricular ejection fraction 40% or less Growth Hormone Deficiency (defined as a peak GH response to intravenous stimulation with GHRH + Arginine &lt; 9 ng/ml) Written Informed consent Acute proliferative or severe nonproliferative diabetic retinopathy Active malignancy Evidence of progression or recurrence of an underlying intracranial tumor Unstable Angina or recent myocardial infarction Serum Creatinine levels &gt; 2.5 mg/dl Severe liver disease (ChildPugh BC)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>